Label evidence
Semaglutide side effects
Semaglutide side-effect percentages depend on which product, route, dose, and study population is being described. Ozempic and Wegovy labels provide several different evidence sets rather than one universal rate. This page focuses on adult injection data and identifies the source of each figure. Oral and higher-dose information remains separate so that a familiar ingredient name does not hide a different study context. Ozempic labelWegovy label
Sources checked
Ozempic: the adult placebo-controlled pool
Ozempic section 6.1 pools two adult type 2 diabetes studies, one as monotherapy and one with basal insulin, described in section 14. Nausea was reported by 15.8% at 0.5 mg and 20.3% at 1 mg, compared with 6.1% on placebo. Vomiting was 5.0% and 9.2%, compared with 2.3%. The table below retains those assigned-dose columns. Ozempic label
The same table reports diarrhea, abdominal pain, and constipation. Constipation was recorded in 5.0% at 0.5 mg and 3.1% at 1 mg, versus 1.5% on placebo. A smaller percentage in the higher-dose column does not turn this pooled comparison into an individual prediction. These data summarize reported events among the enrolled participants under the study conditions. Ozempic label
| Reaction | Placebo | 0.5 mg | 1 mg |
|---|---|---|---|
| Nausea | 6.1% | 15.8% | 20.3% |
| Vomiting | 2.3% | 5.0% | 9.2% |
| Diarrhea | 1.9% | 8.5% | 8.8% |
| Abdominal pain | 4.6% | 7.3% | 5.7% |
| Constipation | 1.5% | 5.0% | 3.1% |
Wegovy: keep the 2.4 mg evidence set identified
Wegovy section 6.1, Table 3, describes the adult 2.4 mg weight-management pool from Studies 2, 3, and 4. Nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, and vomiting in 24% versus 6%. Constipation was 24% versus 11%, while fatigue was 11% versus 5%. The fatigue grouping includes asthenia. These figures belong to this particular pooled population. Wegovy label
The current label separately reports a 7.2 mg injection evidence set from Studies 8 and 9 and an oral 25 mg study identified as Study 7. Those sections are not merged into the 2.4 mg percentages here. A page about semaglutide should preserve such distinctions instead of placing every number under a single ingredient heading with no dose or route attached. Wegovy label
What the labels say about interpretation
The labels caution against directly comparing adverse-reaction rates from differently conducted studies. The Ozempic pooled data says that most nausea, vomiting, and diarrhea reports occurred during escalation. This describes those reported symptoms in that dataset; it does not assign the same timing to all possible reactions or explain a symptom in an individual reader. Ozempic labelWegovy label
Postmarketing experience is another category. Voluntary reports come from a population whose size is uncertain, and the labels explain that a frequency or causal relationship cannot always be reliably established. This is why a list of reported events does not support inventing an incidence percentage. The original adverse-reaction section remains linked for readers who need the full context. Ozempic labelWegovy label
A dated symptom record has a limited, useful role
PinPoint supports side effects with severity ratings and daily notes. Its injection logs include the compound, amount, site, and pain level, and earlier doses can be backfilled. The combination can preserve an observation alongside a recorded phase change. It does not decide whether semaglutide caused the observation, and modeled levels are not personal laboratory measurements. App features
The app provides PDF, CSV, and JSON export for reviewing the history. A clear account retains the product, route, dose date, and wording of the observation rather than relying on a generic symptom label alone. Talk to the prescriber about new, persistent, or concerning symptoms. App features
Useful distinctions
Questions
Can Ozempic and Wegovy percentages be compared directly?
The labels warn that differently conducted studies cannot be directly compared. Their populations, doses, and evidence sets differ, so this page identifies the source context instead of ranking the products. Ozempic labelWegovy label
Does this page give one rate for oral semaglutide too?
No. The oral evidence is distinct. The injection percentages shown here are identified by product and study pool, and they are not presented as tablet rates. Wegovy labelRybelsus label
Your record, together
Keep the details attached to the date.
Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.
Get PinPoint on the App StoreSources & scope
Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.
- PinPoint feature description
Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.
- How to read this reference
Editorial organization, explicit scope limits, and interpretation of the cited label or app evidence. No additional medical facts.
- Ozempic prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
adec4fd2-6858-4c99-91d4-531f5f2a2d79. - Rybelsus prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
27f15fac-7d98-4114-a2ec-92494a91da98. - Wegovy prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
ee06186f-2aa3-4990-a760-757579d8f77b.